Care of the Post-Cardiac Surgery Patient. Lundy J. Campbell, M.D. Associate Professor University of California
|
|
- Thomasina Hill
- 7 years ago
- Views:
Transcription
1 Care of the Post-Cardiac Surgery Patient Lundy J. Campbell, M.D. Associate Professor University of California
2 Post-Operative Issues Post-op atrial fibrillation Acute kidney injury Acute respiratory failure Post-operative glycemic control Deep sternal wound infection Blood transfusion Stroke
3 Post-Operative Issues Post-op atrial fibrillation Acute kidney injury Acute respiratory failure Post-operative glycemic control Deep sternal wound infection Blood transfusion Stroke
4 Atrial Fibrillation Post-op incidence Historically CABG 11-40% All CT 10-65% Increasing incidence with increasing age 24% increasing frequency with each add l 5 yr Initially thought to be more of a nuisance Long-term morbidity/mortality?
5 Atrial Fibrillation After Isolated Coronary Surgery Affects Late Survival 1832 patient prospective observational study No history of permanent afib prior to surgery Patient management and anesthesia technique standardized 31% patients developed afib post op Longer hospital LOS Increased hospital and long-term mortality Adjusted hazard ratio for afib 2.13 based on propensity scoring Mariscalco, et al. Circulation 2008;118;
6 Kaplan-Meier survival estimates according to the occurrence of postoperative AF Mariscalco, G. et al. Circulation 2008;118: Copyright 2008 American Heart Association
7 New Onset A-Fib After Isolated CABG and Long-Term Survival Single-center, retrospective observational study of 6899 consecutive patients without pre-op a-fib 26% developed a-fib post-op 10 year unadjusted survival: 52.3% with post-op a-fib 69.4% no post-op a-fib Risk adjusted to STS mortality risk factors HTN, CHF, PVD, DM, EF, IABP, resp failure, etc Afib increased risk of adjusted mortality by 29% Filardo, G. et al. Circ Cardiovasc Qual Outcomes 2009;2:
8 Effect of new-onset postoperative AFIB on survival in CABG surgery patients Filardo, G. et al. Circ Cardiovasc Qual Outcomes 2009;2: Copyright 2009 American Heart Association
9 New Onset A-fib and Long-Term Mortality After CABG Single center, retrospective observational study of 16,169 consecutive CABG patients OPCABG in 41.5% of patients Propensity adjusted to STS risk factors Post-operative a-fib occurred in 18.5% of patients Chami, et al. JACC Vol 55, no 13, 2010:1370-6
10 New Onset A-fib and Long-Term Adjusted HR 1.21 Mortality After CABG At 1 yr: 96.3% vs 90.1% survival At 10 yrs: 70.2% vs 55.2% survival Only 20.5% of patients in a-fib discharged with warfarin Patients in a-fib less likely to get betablocker, statin or anti-platelet therapy Adjusting for warfarin: HR % relative reduction in mortality Chami, et al. JACC Vol 55, no 13, 2010:1370-6
11 Adjusted Kaplan-Meier Survival Curves Chami, et al. JACC Vol 55, no 13, 2010:1370-6
12 Post-Operative Atrial Fibrillation Increased short and long term mortality Increased with age and severity of illness Warfarin, betablockade, amiodarone, atrial pacing shown to be protective Likely no difference in CABG or OPCABG
13 Acute Renal Failure Studies of renal failure post-ct surgery limited by lack of uniform ARF (AKI) definition. Historical risk of ARF post CT-surgery 5-31% depending on criteria Up to 30% of CT surgery patients develop clinically important renal failure 1-2% require dialysis Conveys approx 8-fold increase risk of death
14 ARF Incidence Large prospective, cohort study (>43,000) VA patients undergoing CT surgery ARF defined as >50% increase in serum Cr from baseline Risk of ARF req dialysis 1.1% 0.9% CABG and 2.0% valve 63.7% mortality in pts with ARF requiring dialysis vs 4.3% in pts without Chertow, G. M. et al. Circulation 1997;95:
15 Risk of acute renal failure with increasing age Chertow, G. M. et al. Circulation 1997;95: Copyright 1997 American Heart Association
16 ARF Post-CABG Mortality Canadian multicenter 3500 pt retospective study. All on pump Patients divided into quartiles 25% decrease in GFR > 25% decrease in GFR (24%) 4 fold increased risk of death > 50% decrease in GFR (7%) 5.9 fold increased risk of death > 75% decrease in GFR (3%) 9.5 fold increased risk of death Karkouti, K. et al. Circulation 2009;119:
17 Risk Factors of Post-Op ARF Duration of CPB Pre-operative use of IABP Pre-operative anemia Pre-operative RBC transfusions Post-operative re-operation Karkouti, K. et al. Circulation 2009;119:
18 Probability of AKI (>50% decrease in egfr or dialysis) Karkouti, K. et al. Circulation 2009;119: Copyright 2009 American Heart Association
19 Pathogenesis of Post-Op Renal Failure Normal autoregulation Normal GFR maintained until MAP<80 Typically MAP<80 on CPB Impaired autoregulation Age, HTN, CRI, atherosclerosis Drugs ACE-I, NSAID, ARB, contrast agents Pro-inflammatory state Operative trauma, reperfusion injury, blood contact with CPB circuit
20 Recent Trends in ARF Mortality Nationwide database CABG patients Estimated 7,339,520 CABG procedures 0.4% patients developed ARF-D ARF-D incidence increased over time 0.22% in 1988 to 0.57% in 2003 Decline in ARF-D mortality over same period 47.4% in 1988 to 29.7% in 2003 Nicoara et al. Blood Purif 2009;28:
21 AKI and OPCABG Meta analysis of 6 RCTs and 16 observational studies Comparing On-Pump CABG with OPCABG Overall found decreased risk in OPCABG (OR 0.57) No difference in AKI requiring dialysis No uniform definition of AKI between studies Am J Kidney Dis 2009;54:
22 Overall Acute Kidney Injury Am J Kidney Dis 2009;54:
23 Acute Kidney Requiring Dialysis Am J Kidney Dis 2009;54:
24 Deep Sternal Wound Infection Historical incidence between 1-3% Reported mortality up to 20% Retrospective study of 3760 consecutive CABG patients from % developed DSWI Predictors DM (OR 5.5) Pre-op hemodynamic instability (OR 3.4) Pre-op renal failure (OR 2.6) Sepsis and/or endocarditis (OR 29.9) Toumpoulis I K et al. Chest 2005;127:
25 Deep Sternal Wound Infection No difference in early mortality Large difference in long-term mortality 1 yr: 93.6 vs 66.2% 5 yrs: 82.3 vs 50.8% 10 yrs 67.3 vs 40.6% Toumpoulis I K et al. Chest 2005;127:
26 Blood Transfusions Association with ARF Association with respiratory failure Association with infections Deep sternal wound infection STS reportable data Are there specific factors important in the CT surgical patient?
27 Age of RBC s Important Decreased deformability Decreased ATP Decreased 2,3 DPG Decreased NO generation Increased adhesion to vascular endothelium
28 Duration of RBC Storage Hypothesis: Older blood worse By FDA: Can transfuse up to 42 days Single-center randomized prospective study 2872 pts got new (<14 days old) blood 3130 pts got old (>14 days old) blood Median storage 11 days in newer arm 20 days in older arm Koch C et al. N Engl J Med 2008;358:
29 Duration of RBC Storage Standard surgical / anesthesia pracitice All patients done on CPB Increased mortality with older blood In hospital: 2.8 vs 1.4% 1 yr: 11 vs 7.4% (NNT 28) Increased morbidity with older blood Intubation > 72 hours: 9.7 vs 5.6% Renal Failure: 2.7 vs 1.6% Sepsis: 4 vs 2.8% Koch C et al. N Engl J Med 2008;358:
30 Kaplan-Meier Estimates of Survival and Death Koch C et al. N Engl J Med 2008;358:
31 Number of Red-Cell Units Transfused in Relation to the Percentage of Patients Receiving Transfusion Koch C et al. N Engl J Med 2008;358:
32 Stroke Incidence approximately 1-2% Multiple associated risk factors Carotid stenosis Prior stroke history Valve surgery Re-do heart surgery Duration of pump time Diabetes Aortic atherosclerosis Recent MI Age > 75 years Low CO Mod/severe LV dysfx HTN CRI Stamou, S. C. et al. Stroke 2001;32:
33 Independent predictors of postoperative stroke after CABG Copyright 2001 American Heart Association Stamou, S. C. et al. Stroke 2001;32:
34 OP-CABG and Stroke Meta-analysis of 41 RCTs comparing offpump and on-pump CABG with stroke risk No difference in mortality on vs off pump Off-pump technique: 50% relaive risk reduction in stroke 30% relative risk reduction in risk of afib 48% relative risk reduction in wound infection Significant increased risk of reintervention (RR1.9) Sedrakyan, A. et al. Stroke 2006;37:
35 Stroke reported in the trials of off-pump surgery Sedrakyan, A. et al. Stroke 2006;37: Copyright 2006 American Heart Association
36 Clinical outcomes in the trials of off-pump surgery Sedrakyan, A. et al. Stroke 2006;37: Copyright 2006 American Heart Association
37 OP-CABG vs On-Pump CABG 2203 VA patients at 18 med centers randomly assigned to on or off-pump CABG Primary short-term endpoint: composite of death or complications Reoperation, new mechanical support, cardiac arrest, coma, stroke, renal failure Primary long-term endpoint: composite of death or: Repeat revascularization procedure, non-fatal MI Shroyer A et al. N Engl J Med 2009;361:
38 Results No significant difference in 30 day composite outcome No difference in overall survival between 2 groups Worse long-term composite outcome for offpump than on-pump patients (9.9 vs 7.4%) Higher proportion of patients with fewer grafts than originally planned with off-pump technique 17.8 vs 11.1% Shroyer A et al. N Engl J Med 2009;361:
39 Kaplan-Meier Estimates of Survival after Surgery Shroyer A et al. N Engl J Med 2009;361:
40 Summary CT surgery patients at high risk for post-op morbidity and mortality Atrial fibrillation Long term mortality risks Treat aggressively to restore SR and anticoagulation Acute kidney injury Incidence increasing due to increasing patient age and severity of illness Overall mortality decreasing due to improved dialysis? OP-CABG benefit
41 Summary Deep sternal wound infection Associated with increased transfusions High mortality Associated with patient severity of illness Blood transfusions Minimize transfusions if possible Evidence to use newer RBCs Stroke Severe morbidity and mortality Occurs during perioperative period? Benefit with OP-CABG
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationNew in Atrial Fibrillation
New in Atrial Fibrillation September 2011 Stroke prevention more options Rhythm Control -drugs - alternatives to drugs; ablation Rate Control - pace + ablate A-FIB Dell Stroke Risk AFib Two Principles
More informationCardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg
Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate
More informationObjectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
More informationPresenter Disclosure Information
2:15 3 pm Managing Arrhythmias in Primary Care Presenter Disclosure Information The following relationships exist related to this presentation: Raul Mitrani, MD, FACC, FHRS: Speakers Bureau for Medtronic.
More informationManagement of Atrial Fibrillation in Heart Failure
Disadvantages of AV Junction Ablation Persistent AFib- no AV synchrony Ongoing risk of thromboembolism Life-long dependency on pacemaker Comparison of LA Ablation vs. AVN Ablation LA Ablation AVN Ablation
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationEndoskopische Venenentnahme der V. saphena in der koronaren Bypasschirurgie - Aktuelle Datenlage - Dr. med. Stefanie Reutter
Endoskopische Venenentnahme der V. saphena in der koronaren Bypasschirurgie - Aktuelle Datenlage - Dr. med. Stefanie Reutter Endoskopische Venenentnahme (EVH) - Einführung 1979 Tevaearai und Kollegen haben
More informationCSI-AKI: the magnitude of the phenomenon Risk factors for CSI-AKI Perfusion-related risk factors What the perfusionist should avoid and what
Cardiac surgery induced acute kidney injury and the perfusionist M. Ranucci Director of Clinical Research Dept of Cardiothoracic and Vascular Anesthesia and Intensive Care IRCCS Policlinico S.Donato Ranuuci,
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationStroke Care First week
Stroke Care First week Florence Nightingale (1820 1910) Stroke Unit Dedicated personnel trained in stroke management Stepwise guidelines supported by explicit checklists Continuous monitoring available
More informationSurgeons Role in Atrial Fibrillation
Atrial Fibrillation Surgeons Role in Atrial Fibrillation Steven J Feldhaus, MD, FACS 2015 Cardiac Symposium September 18, 2015 Stages of Atrial Fibrillation Paroxysmal (Intermittent) Persistent (Continuous)
More informationNone. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationPRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf
More informationRenovascular Hypertension
Renovascular Hypertension Philip Stockwell, MD Assistant Professor of Medicine (Clinical) Warren Alpert School of Medicine Cardiology for the Primary Care Provider September 28, 201 Renovascular Hypertension
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationListen to your heart: Good Cardiovascular Health for Life
Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular
More informationPHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1
More informationOmega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9
Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer
More information1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using
What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI
More informationNew Anticoagulants and GI bleeding
New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit
More informationManagement of Symptomatic Atrial Fibrillation
Management of Symptomatic Atrial Fibrillation John F. MacGregor, MD, FHRS Associate Medical Director, Cardiac Electrophysiology PeaceHealth St. Joseph Medical Center, Bellingham, WA September 18, 2015
More informationDISCLOSURE. Atrial Fibrillation Management An Evidence-based Approach OBJECTIVES BACKGROUND AFFIRM 9/16/2015
Death (%) Mortality (%) 9/16/2015 DISCLOSURE Atrial Fibrillation Management An Evidence-based Approach Jonathon Adams, MD, FHRS Relevant Financial Relationship(s) None Off Label Usage None OBJECTIVES What
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationMitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation. Michael Acker, MD For the CTSN Investigators AHA November 2013
Mitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation Michael Acker, MD For the CTSN Investigators AHA November 2013 Acknowledgements Supported by U01 HL088942 Cardiothoracic
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationPerioperative Risk Stratification for Noncardiac Surgical Patients with Cardiac Diagnosis. Michael A. Blazing
Perioperative Risk Stratification for Noncardiac Surgical Patients with Cardiac Diagnosis Michael A. Blazing Outline The coming crush A practical approach to clinical risk assessment Classic approach to
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More information8-9-2012. In hospital diabetes care background and challenges. Duality of interest. One of the goals may be...
In hospital diabetes care background and challenges Duality of interest Nothing to disclose within the framework of this presentation My own fasting BG is 4.6 mmol/l, HbA1c 5.4% Bruce H.R. Wolffenbuttel
More informationTo Bridge or Not to Bridge. Periop Anticoagulation Management. Don Weinshenker, MD Ambulatory Care Denver VAMC
To Bridge or Not to Bridge Periop Anticoagulation Management Don Weinshenker, MD Ambulatory Care Denver VAMC Financial Disclosure Information Nothing to report Periop AC Management Chronically anti-coagulated
More informationElevated heart rate at twelve months after heart transplantation is an independent predictor of long term mortality
Elevated heart rate at twelve months after heart transplantation is an independent predictor of long term mortality C. Tomas, MA Castel, E Roig, I. Vallejos, C. Plata, F. Pérez-Villa Cardiology Department,
More informationHow do you decide on rate versus rhythm control?
How do you decide on rate versus rhythm control? Dr. Mark O Neill Consultant Cardiologist & Electrophysiologist Assumptions Camm et al. EHJ 2010;Sept 25 epub Choice of strategy: Criteria for consideration
More informationRuchika D. Husa, MD, MS Assistant t Professor of Medicine in the Division of Cardiology The Ohio State University Wexner Medical Center
Modified Early Warning Score (MEWS) Ruchika D. Husa, MD, MS Assistant t Professor of Medicine i in the Division of Cardiology The Ohio State University Wexner Medical Center MEWS Simple physiological scoring
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
More informationTreating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
More informationIntroduction to Blood Management
Introduction to Blood Management What is Blood Management? Preventing a blood transfusion to the patient who doesn t need one Right blood product, at the right time, in the right dose, to the right patient
More informationDenominator Statement: Cardiac surgery patients with no evidence of prior infection.
Last Updated: Version 4.3b NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Information Form CMS/The Joint Commission: Suspended (Effective immediately beginning with July 1, 2014 discharges)
More informationHow do you decide on rate versus rhythm control?
Heart Rhythm Congress 2014 How do you decide on rate versus rhythm control? Dr Ed Duncan Consultant Cardiologist & Electrophysiologist Define Rhythm Control DC Cardioversion Pharmacological AFFIRM study
More informationAtrial Fibrillation in the ICU: Attempting to defend 4 controversial statements
Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements Salmaan Kanji, Pharm.D. The Ottawa Hospital The Ottawa Hospital Research Institute Conflict of Interest No financial, proprietary
More informationSporadic or short episodes of paroxysmal atrial fibrillation - still a need for antithrombotic therapy?
Sporadic or short episodes of paroxysmal atrial fibrillation - still a need for antithrombotic therapy? Carina Blomström Lundqvist Dept Cardiology, Uppsala University, Sweden Patterns of AF Terminates
More informationPerioperative Cardiac Evaluation
Perioperative Cardiac Evaluation Caroline McKillop Advisor: Dr. Tam Psenka 10-3-2007 Importance of Cardiac Guidelines -Used multiple times every day -Patient Safety -Part of Surgical Care Improvement Project
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationVasopressors. Judith Hellman, M.D. Associate Professor Anesthesia and Perioperative Care University of California, San Francisco
Vasopressors Judith Hellman, M.D. Associate Professor Anesthesia and Perioperative Care University of California, San Francisco Overview Define shock states Review drugs commonly used to treat hypotension
More informationUtilizing the Cath Lab for Cardiac Arrest
Utilizing the Cath Lab for Cardiac Arrest Khaled M. Ziada, MD Director, Cardiovascular Catheterization Laboratories Gill Heart Institute, University of Kentucky UK/AHA Strive to Revive Symposium May 2013
More informationStroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2
Bleeding/Clotting Risk Evaluation Tools for Atrial Fibrillation Patients Before prescribing anticoagulants, providers should weigh the risk of thrombosis against the risk of bleeding. The tools below can
More informationAtrial Fibrillation The Basics
Atrial Fibrillation The Basics Family Practice Symposium Tim McAveney, M.D. 10/23/09 Objectives Review the fundamentals of managing afib Discuss the risks for stroke and the indications for anticoagulation
More informationGUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY
BLOOD CONSERVATION STRATEGIES IN CARDIAC SURGERY: MORE IS BETTER GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY DIMITRIOS V. AVGERINOS MD, PhD, FACS, FACC Department of Cardiac Surgery,
More informationMANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING
More informationTranexamic Acid. Tranexamic Acid. Overview. Blood Conservation Strategies. Blood Conservation Strategies. Blood Conservation Strategies
Overview Where We Use It And Why Andreas Antoniou, M.D., M.Sc. Department of Anesthesia and Perioperative Medicine University of Western Ontario November 14 th, 2009 Hemostasis Fibrinolysis Aprotinin and
More informationManagement of Pacing Wires After Cardiac Surgery
Management of Pacing Wires After Cardiac Surgery David E. Lizotte, Jr. PA C, MPAS, FAPACVS President, Association of Physician Assistants in Cardiovascular Surgery Conflicts: None Indications 2008 Journal
More informationSecondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
More informationRATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
More informationAnticoagulation Therapy Update
Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More information2/20/2015. Cardiac Evaluation of Potential Solid Organ Transplant Recipients. Issues Specific to Transplantation. Kidney Transplantation.
DISCLOSURES I have no relevant financial relationships to disclose. Cardiac Evaluation of Potential Solid Organ Transplant Recipients Michele Hamilton, MD Director, Heart Failure Program Cedars Sinai Heart
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationAtrial Fibrillation: Drugs, Ablation, or Benign Neglect. Robert Kennedy, MD October 10, 2015
Atrial Fibrillation: Drugs, Ablation, or Benign Neglect Robert Kennedy, MD October 10, 2015 Definitions 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary.
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationOptimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015
Optimizing Anticoagulation Selection for Your Patient C. Andrew Brian MD, FACC NCVH 2015 Who Needs to Be Anticoagulated and What is the Patient s Risk? 1. Atrial Fibrillation ( nonvalvular ) 2. What regimen
More informationNew Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine
New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine Disclosures & Relevant Relationships I have nothing to disclose No financial conflicts Editor,
More informationESCMID Online Lecture Library. by author
Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare
More informationPalpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust
Palpitations & AF Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust Palpitations Frequent symptom Less than 50% associated with arrhythmia
More informationAtrial Fibrillation and Cardiac Device Therapy RAKESH LATCHAMSETTY, MD DIVISION OF ELECTROPHYSIOLOGY UNIVERSITY OF MICHIGAN HOSPITAL ANN ARBOR, MI
Atrial Fibrillation and Cardiac Device Therapy RAKESH LATCHAMSETTY, MD DIVISION OF ELECTROPHYSIOLOGY UNIVERSITY OF MICHIGAN HOSPITAL ANN ARBOR, MI Outline Atrial Fibrillation What is it? What are the associated
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationHow To Improve A Hospital'S Performance
FY 16 MHAC Methodology Redesign HSCRC Performance Measurement Work Group February 20, 2014 1 Presentation Contents Background: Reason to change, guiding principles, timing Measurement Methodology Payment
More informationSteven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From the CoreValve US Pivotal Trial Steven J. Yakubov,
More informationOptimal fluid therapy in 2013. Eric Hoste Department of Intensive Care Medicine Ghent University Hospital Ghent University
Optimal fluid therapy in 2013 Eric Hoste Department of Intensive Care Medicine Ghent University Hospital Ghent University EGDT: fluids are good & prevent AKI Lin et al, Shock 2006 EGDT and AKI Prowle et
More informationAtrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE
Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with
More informationTreatment of Cardiac Device Infections
Treatment of Cardiac Device Infections Peter Ammann 2 2 40 yrs old patient Pocket infection after pacemaker change. Staph. aureus growing in blood cultures. Pacemaker dependent. Echo: no vegetations on
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationRR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) 3.75
ALL-CAUSE MORTALITY RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) Rate per year (%) 5.0 4.0 3.0 2.0 1.0 0 3.64 D150 mg BID 3.75 D110 mg BID RR 0.91 (95% CI: 0.80 1.03) P=0.13 (superiority) 4.13 Warfarin
More informationPREOPERATIVE CARDIAC RISK FOR NONCARDIAC SURGERY Review of 2014 ACC/AHA Guidelines and Implications for Clinical Care
PREOPERATIVE CARDIAC RISK FOR NONCARDIAC SURGERY Review of 2014 ACC/AHA Guidelines and Implications for Clinical Care Ronald L Walsh, D.O., MACOI, FACC ACOI Clinical Challenges in Inpatient Care March
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationAtrial Fibrillation An update on diagnosis and management
Dr Arvind Vasudeva Consultant Cardiologist Atrial Fibrillation An update on diagnosis and management Atrial fibrillation (AF) remains the commonest disturbance of cardiac rhythm seen in clinical practice.
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationAtrial Fibrillation Management Across the Spectrum of Illness
Disclosures Atrial Fibrillation Management Across the Spectrum of Illness NONE Barbara Birriel, MSN, ACNP-BC, FCCM The Pennsylvania State University Objectives AF Discuss the pathophysiology, diagnosis,
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationAortic Valve Stenosis and CAD
EUROECHO 14, Copenhagen 2010 Aortic Valve Stenosis and CAD Aleksandar N. Neskovic Clinical Hospital Center Zemun Belgrade University School of Medicine Aortic Stenosis and CAD Important facts Links AS/CAD
More informationTranscatheter Mitral Valve-in-Valve and Valve-in-Ring Implantations. Danny Dvir, MD On behalf of VIVID registry investigators
Transcatheter Mitral Valve-in-Valve and Valve-in-Ring Implantations Danny Dvir, MD On behalf of VIVID registry investigators Introduction Bioprosthetic valves are increasingly implanted in open-heart surgeries.
More informationDepartment of Pharmacy, Kaiser Permanente San Francisco Medical Center, San Francisco 94115, California, USA
Journal of Pharmacy and Pharmacology 3 (2015) 33-38 doi: 10.17265/2328-2150/2015.01.005 D DAVID PUBLISHING Evaluation of Glycemic Control with a Pharmacist-Managed Post-Cardiothoracic Surgery Insulin Protocol
More informationMechanical Circulatory Support and End of Life Care. 10 th Annual Interdisciplinary Transplant Symposium 24 September 2015
Mechanical Circulatory Support and End of Life Care 10 th Annual Interdisciplinary Transplant Symposium 24 September 2015 Nicole Huhn, APRN VAD Coordinator Center for Advanced Heart Failure & Transplant
More informationDUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania
DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen
More informationManagement of Antithrombotics with Procedures. Jordan Weinstein, MD
Management of Antithrombotics with Procedures Jordan Weinstein, MD Presenter Disclosure Information Cardiology Update 2013 I have no relevant financial interest and/or arrangement with industry. Novel
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationMarco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo
Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo Acute Coronary Syndromes: oral antithrombotic therapy Focus on
More informationCardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
More informationAddendum to Clinical Review for NDA 22-512
Addendum to Clinical Review for DA 22-512 Drug: Sponsor: Indication: Division: Reviewers: dabigatran (Pradaxa) Boehringer Ingelheim Prevention of stroke and systemic embolism in atrial fibrillation Division
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY
Measure #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS,
More informationEvidence-Based Secondary Stroke Prevention and Adherence to Guidelines
Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines Mitchell S.V. Elkind, MD, MS Associate Professor of Neurology Columbia University New York, NY Presenter Disclosure Information Mitchell
More informationKDIGO THE GEORGE INSTITUTE FOR GLOBAL HEALTH. Antiocoagulation in diabetes and CKD Vlado Perkovic
THE GEORGE INSTITUTE FOR GLOBAL HEALTH Antiocoagulation in diabetes and CKD Vlado Perkovic Executive Director, George Institute Australia Professor of Medicine, University of Sydney Affiliated with the
More informationDCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study
DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study National Diabetes Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What
More informationEfficient Evaluation of Chest Pain
Efficient Evaluation of Chest Pain Vikranth Gongidi, DO FACC FACOI Indian River Medical Center Vero Beach, FL No Disclosures Outline Background Chest pain pathway Indications for stress test Stress test
More information